Shots:

• The P-III GEMINI 1 study involves assessing AGN-190584 (pilocarpine 1.25%- qd) ophthalmic solution in 323 patients in a ratio (1:1) with presbyopia for 30days.
• The study demonstrated that AGN-190584 met both its 1EPs & 2EPs with patients achieving near & intermediate vision gains. In addition- AGN-190584 showed no loss of distance vision- rapid onset of action and sustained vision gains of up to 6hrs.
• PRO data showed improvement in ability and satisfaction in near vision reading as well as a reduction in the use of presbyopia coping mechanisms during the last 7days of the trial. If approved- AGN-190584 is expected to be the first eye drop for presbyopia

­ Ref: PRNewswire  | Image:abbvie